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Abstract
Prescription medication is typically prescribed with a stan-
dardised set of instructions, to be followed regularly, with the
aim being to manage symptoms while remaining within safe
dosage limits. The caveat of such standardisation is that it is
not tailored to the needs of the patient, in terms of their activ-
ities. In this paper, we take the first steps towards modelling
medication pharmacokinetics as a PDDL+ hybrid planning
problem. As pharmacokinetics are inherently non-linear, we
present a planner-independent linearise–validate cycle, where
tasks can be solved by iterative refinement of a linear approxi-
mation of the domain, by validation against the full non-linear
semantics.
1 Introduction
One of the largest problems in healthcare is the incorrect
consumption of medication. It is estimated that half of pa-
tients that are prescribed medication for chronic conditions
do not consume their medication correctly (The Academy of
Medical Sciences 2014). Most medication is prescribed in
a way that expects the patient to follow a standard routine.
This is done in order to help the patient stay compliant and at
the same time to consume the medication in a way that does
not endanger the patient – often, when patients are given a
regular dose, it is to keep things simple. For example, parac-
etamol (acetaminophen) is usually given in doses of 500mg
per pill. The standard dose is two pills to be taken every four
to six hours, with a maximum consumption of eight pills per
day. Higher levels may give more pain relief, but the rate at
which it is metabolised gives a risk of paracetamol toxicity
if these limits are exceed – the spacing between doses, and
daily limit, avoid excess exposure.
To address the challenge of effectively managing patients’
medication usage, one option is to produce personalised
medication plans. Personalised medicine is defined by the
as providing “the right patient with the right drug at the
right dose at the right time” (Sadee and Dai 2005). His-
torically, the scope for this has been limited to where it is
essential (for instance, personalised insulin regimes for di-
abetics) but is recently becoming more viable through the
uptake of technology – at one extreme, with the use of a
drug dosage printer to ‘print’ drugs with accurately specific
doses (Hirshfield et al. 2014).
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In this paper we present the possibility of using PDDL+
to personalise medication schedules by modelling the prob-
lem as a hybrid planning domain, determining an effective
schedule for a patient depending on their varying pain relief
needs throughout the day. As the metabolism of medication
is non-linear (negative exponential), and many otherwise-
effective PDDL planners do not support non-linear domains,
we explore the use of an iterative piece-wise linear approx-
imation process to allow a broader range of planners to be
used as a kernel within this process; and hence find solutions
that are valid when considering the full non-linear pharma-
cokinetics. We present an initial evaluation of this approach
using the planner OPTIC (Benton, Coles, and Coles 2012),
as extended to support PDDL+ (Coles and Coles 2014), and
discuss the future direction of the work and limitations of
PDDL+ for modelling desirable objective functions in this
domain.
2 Background
When consumed, medication is metabolised in the body
over time, leading to a decay of the active medication level.
Whilst pharmacokinetics are complex, a reasonable model is
to assume negative-exponential (i.e. first-order) decay, with
drug-dependent half-lives depending on the rate at which the
active ingredients are metabolised (Geenen et al. 2013). Re-
turning to the example of Paracetamol, the half life is up to
3 hours. That means if someone takes 1000mg of paraceta-
mol at 12.00pm, there will be 500mg of the drug left in three
hours (i.e. at 3.00pm). In another three hours (i.e. 6.00pm),
there will be 250mg of the drug left, and so on. The ques-
tion then, returning to the topic of this paper, is how these
pharmacokinetics can be modelled in PDDL.
Medication levels changing over time are an example of
continuous numeric change. The capability for these was
first added to PDDL in PDDL2.1 (Fox and Long 2003), as
part of ‘layer 5’ – durative actions can have continuous nu-
meric effects that occur during their execution. As drug
metabolism is not something that one can choose to occur
in a plan, but is rather something that occurs exogenously in
the world, a better fit is to encode it as a process, expressed in
PDDL+ (Fox and Long 2006). PDDL+ provides a language
for defining hybrid planning problems, where the state tra-
jectory for a solution plan contains the effects of the planned
actions (as in PDDL2.1) but also the consequences of ex-
ogenous processes and events. The key distinction is that a
process occurs whenever its conditions are true: it stops and
starts, outwith the direct control of the planned actions; and
during its execution, it effects continuous numeric change
upon the world. Analogously, PDDL+ events are instanta-
neous actions that occur whenever their conditions are true:
when they fire, the world is immediately updated according
to their instantaneously effects. By combining these, PDDL+
provides a useful toolkit for expressing hybrid domain mod-
els for a range of problems (Piotrowski et al. 2015). In this
paper, as we will illustrate, we combine these to provide the
necessary exogenous context in which to plan personalise
medication consumption schedules.
3 High-level Problem Description
The decision-making constraints for a given medication can
be defined using a number of constants:
• t1/2, its biological half life. This is the time taken for the
plasma level of the medication to halve.
• B, the typical dose amount consumed.
• G, the amount of time one needs to leave between two
doses.
• m, the maximum number of doses within the planning
horizon (e.g. 24 hours).
Given the half life, and the plasma level of a drug, D,
the rate r at which the plasma concentration of the drug is
decreasing can be calculated as:
r = D · ln 2
t1/2
Taking the integral of this, the level of a drug at a time t
(D(t)) after some reference point (D0) can be written as:
D(t) =
D0
2
t
t1/2
As we are planning the consumption of medication, we
can think of the trajectory of drug levels during a solution
plan as comprising time points at which medication is taken
(when the drug level increases), interspersed with intervals
in which the medication level reduces with rate r. More
formally:
• At time t0, the medication level takes some pre-defined
value D0 (the initial plasma level).
• At subsequent ordered time points [t1..tn−1] an amount
of medication [B1..Bn−1] is taken. For this paper, we
assume these values are either 0 orB – the dose that could
in principle be consumed.
• At time tn, no medication is taken – this represents the
end of a finite horizon over which the plan must succeed.
With this representation, we can define the constraints on
medication consumption. First, if a dose is taken at time ti,
the next dose cannot be taken at a time before ti + G:
∀
i∈[1..n]
(
Bi = 0 ∨
(
∀
j∈[i+1..n]
(Bj = 0 ∨ tj − ti ≥ G)
))
Second, the maximum number of doses within the plan-
ning horizon is m:
|{i · i ∈ [1..n− 1] ∧Bi 6= 0}| ≤ m
A medication plan can be said to be safe if it satisfies these
two constraints. A separate matter is what therapeutic bene-
fit is provided: taking no medication at all never exceeds the
limits of the prescription, but of course is of no benefit to the
patient. The medication level D(ti) at time ti (i > 0) can be
defined as:
D(ti) =
D(ti−1) + Bi−1
2
ti−ti−1
t1/2
The interaction between planning decisions and plasma
levels arises when considering how a plan may constrain
what are permissible drug levels at different points within
the planning horizon.
In this paper we will focus on pain relief management
with a single painkiller as an exemplar problem, so can dis-
cuss drug levels in terms of desired levels of pain relief (pr).
In the simple case, the schedule of desired pain relief is
static: at defined intervals throughout the day, the pain relief
must be no lower than a minimum threshold. For instance,
suppose a patient goes to work at 9am every morning and
finishes work at 5pm every evening. We could then expect
the minimum pain relief to be higher within this interval than
at other times.
More persuasively, from a planning point of view, the de-
sired pain relief is dynamic, depending on the actions used
in the plan. For instance, during some actions (shopping
for groceries, walking, and so on) a greater level of pain re-
lief may be needed than at other times. A plan then must
have a reasonable causal structure – as would be the case for
planning a user’s day modulo medication requirements – but
additionally, the actions may have preconditions referring to
pain relief that must hold during their execution. To meet
these, in turn, requires the use of actions that correspond to
taking medication. The resulting plan then gives the patients
a personalised schedule of times at which they should take
their medication, along with a plan for the day for their other
activities, to ensure they get the right pain relief at the right
time.
4 Modelling Pharmacokinetics in PDDL+
Having now set out the mathematical model of medication
levels that we will use, we now map this to PDDL+.
First, to model the pharmacokinetics, a process is used.
This runs whenever there is a non-zero amount of medica-
tion in the bloodstream; and decreases the medication level
at rate r. In our example of single-medication pain relief,
the variable pr represents pain relief, and ke represents the
elimination constant for the medication:
ke =
ln 2
t1/2
The process can then be written as follows:
(:process decay
:parameters ()
:precondition
(> (pr) 0)
:effect
(decrease (pr) (* #t (* (pr) (ke))))
)
For clarity, the ‘decrease’ line can be read as:
−dpr
dt
= pr · ke
Alongside this process, there is one action that changes
pr : consume. This is a durative action with duration G and
has the following preconditions and effects:
• To start the action, a proposition safe-to-consume (true
initially) must be true; and a variable doses (0 initially)
must be less than m (the maximum number of doses).
• When started, safe-to-consume is deleted; doses is in-
creased by 1; and the pain relief level pr is increased by
B – the dose of medication.
• At the end of the action, safe-to-consume is added
Effectively, safe-to-consume and doses perform the req-
uisite book-keeping to enforce the constraints on maxi-
mum medication consumption. safe-to-consume acts as a
semaphore: no two consume actions can overlap; and the
duration G serves to ensure the minimum specified time be-
tween doses is thereby respected. doses is a simple counter,
to ensure that if a dose is to be taken, the maximum safe
limit for the period over which we are planning cannot be
exceeded.
Having defined the pharmacokinetics, and constrained
medication taking, what is left is to define the minimum pain
relief. For the case of a static minimum pain relief sched-
ule, the minimum pain relief level minpr can be set using
Timed Initial Fluents (Piacentini, Fox, and Long 2015) (TIF)
– these specify the new value for minpr at each time it needs
to change. For instance, taking plan time units to be minutes
counting from midnight:
(= (minpr) 0)
(at 420 (= (minpr) 100))
(at 540 (= (minpr) 200))
(at 1020 (= (minpr) 100))
(at 1320 (= (minpr) 0))
...sets the minimum pain relief to 100 at time 420 (7:00),
to 200 at time 540 (9:00), then back down to 100 and 0 later
in the day.
Having set the schedule, to ensure at all times pr ≥
minpr , we use a PDDL+ event that fires at the first time
this is not the case:
(:event prfailure
:parameters ()
:precondition (and
(< (pr) (minpr))
(min-check-passed)
)
:effect
(not (min-check-passed))
)
The proposition min-check-passed is true in the initial
state, required as a goal, and not added by any other ac-
tion. Hence, if at any point in the plan the value of pr falls
below minpr , the proposition is deleted, and a dead-end is
reached: it is impossible to re-achieve this goal.
For dynamic pain relief levels, as set by actions, this is
somewhat simpler: if an action requires some level of mini-
mum pain relief during its execution, then this can be added
as an over all condition, for instance:
(over all (>= (pr) 300))
...will ensure that the pain relief level is at least 300 dur-
ing the execution of the action. The ‘TIF plus event’ model
of a static pain relief schedule is unaffected, as this condi-
tion alone ensures that there is enough pain relief during the
execution of the action.
The practical upshot of this PDDL+ encoding is that it
allows a pharmacokinetic model to be specified as a back-
ground context into which a planning model can be speci-
fied.
5 Planning using a LineariseÞ Validate
Cycle
In our initial experimentation with our PDDL+ model as
specified thus far, a restricted range of planners were found
that could reason with the negative-exponential numeric
change induced by the process (e.g. UPMURPHI (Penna et
al. 2009) and DINO (Piotrowski et al. 2015)); and some that
could reason with processes, but only if the effects are lin-
ear (e.g. the extension of OPTIC described in (Coles and
Coles 2014)). There is something of a trade-off between
these two classes of planner. UPMURPHI et al. are capa-
ble of handling negative-exponentials and other non-linear
domain features, and have been used in a number of ap-
plications including battery load management (Fox, Long,
and Magazzeni 2012). Conversely, if linear change is suffi-
cient, OPTIC’s heuristic forward-search approach is a good
choice; but, assuming pharmacokinetics are linear is not rea-
sonable1.
Desiring to maintain the benefits of using OPTIC, we
present an iterative approach where a linear approximation
is incrementally refined until the plans found are valid ac-
cording to the non-linear domain model. This is related to
the discretise–validate approach of UPMurphi, but instead
of discretising time (notionally, on the X-axis), we linearise
by segmenting the values of variables (on the Y-axis).
1Zero-order pharmacokinetics are rare; one notable exception
is ethanol, but this has a narrow range of medical applications.
Figure 1: Initial Linear Approximation
As a starting point, we must devise an initial linear ap-
proximation. For this, we refer to:
• lb, the lower bound on what is an interesting medication
level. This cannot be 0, as mathematically, a negative ex-
ponentially decreasing drug plasma level will only reach
0 as t → ∞. We instead use a nominal value of 1% of a
dose (for paracetamol, a value of 10, i.e 10mg).
• ub, the upper bound on what is an interesting medication
level. This corresponds to taking the maximum number
of doses m in succession, with each dose separated by the
minimum time between doses, G.
• rub,lb , the average medication decay rate over the time
taken for the plasma level to fall from ub to lb:
rub,lb =
ub − lb
−t1/2
ln 2 · ln( lbub )
This is depicted in Figure 1. The solid line shows the
negative-exponential change in pain relief, assuming the
pain relief at time 0 is ub. The x-axis ranges from 0 until
the time at which the pain relief level would reach lb. The
dotted line shows a linear approximation spanning this time,
with gradient rub,lb .
A substantial caveat is that the initial linear approximation
substantially over-estimates pain relief. If there is a mini-
mum pain relief threshold (e.g. the dashed line in Figure 1),
then actual pain relief will fall below the threshold far sooner
than would be considered to be the case according to the lin-
ear approximation. But, we do get a simple linear process,
with a constant (linear) effect:
(:process decay_ub_lb
:parameters ()
:precondition
(and (>= (pr) lb) (<= (pr) ub))
:effect
(decrease (pr) (* #t r_ub_lb))
)
Solving this linearised problem, then validating the plan
against the non-linear model using VAL (Howey, Long, and
Fox 2004), will identify where the inaccuracies inherent in
the linearisation have caused issues. This is evidenced in
one of two ways:
Algorithm 1: Linearise–Validate Cycle
Data: P , the non-linear planning domain and problem;
bounds = {ub, lb}, the initial bounds
Result: A solution plan, Π
Pbase ← P , with the decay process removed;1
while true do2
sorted ← [bounds , sorted in descending order];3
P ′ ← Pbase , with a linear process for each4
successive pair in sorted ;
Π← solve P ′ using planner;5
if Π is a valid solution to P then return Π;6
foreach pr ∈ VAL’s diagnostic trace for Π using7
model P do
bounds ← bounds ∪ {pr}8
• The event prfailure occurred, deleting
(min-check-passed) – as this is a goal, the
solution plan is invalid.
• A precondition on an action referring to pr was unsatis-
fied at some time – and hence the solution plan is invalid.
In both of these cases, VAL produces a diagnostic trace: a
time-stamped progression through the plan, including what
the value of pr was at each happening in the plan, as eval-
uated against the non-linear domain. With this information,
we can refine the linearisation: instead of having a single-
segment linear process spanning the whole range ub to lb,
we can have several processes each covering one segment of
this range.
Our motivation for refining the linearisation to give the
right value of pr at happenings is based the observation that
error in the linearisation is acceptable, so long it gives the
right value when it matters; i.e. when prfailure would
fire, or a precondition referring to pr would be violated.
Hence, we ensure that on each iteration, the plan found with
the previous linearisation will not be admitted by the new
linearisation. This does not guarantee that a solution to the
non-linear model will be found on the second iteration, but
it does mean the model is iteratively refined to exclude ap-
parently attractive but actually infeasible solutions.
Our approach is shown in Algorithm 1. We begin by run-
ning the planner to find a solution based on the initial ap-
proximation; i.e. starting with the initial values of ub and lb.
Hence, at line 4, when the linearised model P ′ is generated,
we have only one pair of bounds in the list, and generate a
single process covering this range, with an effect with gra-
dient rub,lb . A solution Π to P ′ is then found.
As noted earlier, it is likely that when using the initial
linearisation, Π will not be a solution to P – as P ′ overes-
timates the actual pain relief throughout the day. Hence, to
refine the linearisation, we refer to the happenings in the di-
agnostic trace from VAL, an example of which can be seen
in Figure 2, and keep all calculated values of pr (marked in
boldface); i.e. for the plan Π, what values of pr were seen
according to the model P . Each of these is added to the
set of bounds (line 8). With this updated set of bounds, the
loop starts again, generating an updated linear problem P ′,
Checking next happening (time 240)
Updating (pr) (1300) by 515.905 assignment
Checking next happening (time 240)
Adding (safe-to-consume)
Checking next happening (time 486.079)
Updating (pr) (515.905) by 200 assignment
EVENT triggered at (time 486.079)
Triggered event (prfailure)
Deleting (min-check-passed)
Checking next happening (time 544.824)
Updating (pr) (200) by 159.509 assignment
...
Checking next happening (time 784.824)
Updating (pr) (1159.51) by 460.152 assignment
Figure 2: Example Stack Trace from VAL
and once again attempting to find a solution plan. For the
updated problem, the bounds are sorted, and a process gen-
erated for each adjacent pair of bounds, each with its own
rub,lb value.
6 Evaluation
As an initial evaluation of our approach, we generated a se-
quence of problems with increasing planning horizon and a
fixed minpr level, thereby necessitating increased number
of doses as problem sizes increases. The planning horizons
tested started at 540 minutes (i.e. 9 hours), and increased by
60 minutes each time.
The reference drug used was paracetamol, with the fol-
lowing initial parameters:
• t1/2 (half life): 180 minutes
• B (dose amount): 1000mg
• G (gap between doses): 240 minutes
• m (max doses): 4 doses
• lb, (lower bound): 10mg
• ub, (upper bound): 3000mg
• minpr: 200mg.
Our linearise–validate cycle was implemented in a
planner-independent way, but the only candidate planner
that yielded solutions was the extension of OPTIC to sup-
port linear PDDL+ (Coles and Coles 2014). A number
of other planners were considered (Cashmore et al. 2016;
Piotrowski et al. 2015; Penna et al. 2009), but publicly avail-
able implementations of planners were unable to solve prob-
lems (non-linear and linear). The results for this configu-
ration are shown in Table 1. All problems were solved in
at most two iterations, with the time for the first iteration
shown in the row tinitial, and for the refined iteration in the
row trefined.
Figure 3: Comparison Between Doses Needed and Planning
Time (in seconds)
For shorter planning horizons, we see some interesting
results.
• For a horizon of 540 minutes, the solution for the initial
linearisation used only a single dose of medication; the
resulting solution did not validate, so the linear model was
refined, and a new plan found.
• For horizons in the range 600–720, the solution for the ini-
tial linearisation recognised the need to take two doses of
medication; and these were taken back-to-back. The re-
sulting plan was incidentally a valid solution for the non-
linear model.
• For a horizon of 780, two doses were needed (as with
600–720) but the timing of the doses is more important:
the second dose needs to be delayed to come somewhat
more than four hours after the first. This was not recog-
nised by the initial linearisation (which over-estimated
pain relief at time 780); but was compensated for in the
refined linearisation by appropriately delaying the second
dose.
For the larger problems, the initial linearisation was never
valid. The planning time for the refined model was strongly
correlated with the number of doses to be taken – this is
shown more clearly in Figure 3, where the planning time
(left Y-axis) tracks the number of doses needed (right Y-
axis).
To gain further insights into the linearisation process, we
looked at the solution plan found for the longest planning
horizon (1260), after the first and second iteration. These
plans were validated against three models:
• The refined linearisation
• The non-linear model (i.e. exponential decay)
• The initial linearisation
Figure 4 shows the calculated value of pr for the plan af-
ter the first iteration, validated against each of these. The
first plan took three doses back-to-back. With reference to
the initial linearisation (the dashed line), this is reasonable –
a fourth dose was not necessary to complete the plan. As can
be seen, the initial approximation is as expected extremely
Planning Horizon (minutes)
540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260
tinitial 0.05 0.03 0.03 0.04 0.03 0.04 0.03 0.03 0.06 0.06 0.06 0.09 0.09
trefined 0.71 - - - 11.72 164.19 162.99 161.29 160.09 110.05 111.2 654.77 649.86
total 0.76 0.03 0.03 0.04 11.75 164.23 163.04 161.32 160.12 110.11 111.26 654.83 649.95
doses 2 2 2 2 2 3 3 3 3 3 3 4 4
Table 1: Planning times (seconds) for fixed minpr , increasing plan horizon
Figure 4: Pain Relief Levels with Three Models, using the
Initial Approximation Plan
ub 3000.0 515.905 515.901 200.0
lb 515.905 515.901 200.0 10.0
rub,lb 5.43373 1.986648 1.283748 0.2442325
Table 2: Example bounds after one iteration (horizon 1260)
optimistic, with the calculated value of pr significantly ex-
ceeding the actual negative-exponential value (the dotted
line). The refined linearisation (solid line) avoids falling into
the same trap: a three-dose solution would cross the minpr
threshold, so would never be returned as a solution by the
planner.
An analogous graph for the plan after the second itera-
tion, found by the planner using the refined linearisation, is
shown in Figure 5. Crucially, a fourth dose is now taken.
In particular, the planner scheduled doses to be taken at the
earliest possible instance for the first three doses (at time
0, 240 and 480) and waited until the latest possible time to
take the fourth dose; i.e. medication was consumed just be-
fore the minpr threshold was crossed, the point at which the
prfailure event would otherwise have fired.
For reference, with a horizon of 1260, five bounds were
used: the initial bounds of 3000 and 10, and a further three
in between. This yielded four linear processes, whose pa-
rameters are shown in Table 2.
To test whether the planner could scale over a horizon be-
yond 1260 minutes, we created a problem with a horizon of
1500 minutes (25 hours), using a Timed Initial Literal (Hoff-
mann and Edelkamp 2005) to mark the point at which the
day changed (to limit doses consumed per 24 hours). Al-
Figure 5: Pain Relief Levels with Three Models, using the
Refined Approximation Plan
though the planner was able to find a solution, needing five
doses, it took almost two hours – adding the Timed Initial
Literal to switch from one day to the next had a substantial
effect on the size of the search space.
7 Discussion and Future Work
With our our linearise–validate approach, we have shown
we can solve problems in this domain, and have presented an
evaluation to show its efficacy on fixed-minimum-pain-relief
tasks. The evaluation problem as it stands could be seen as a
scheduling problem rather than a planning problem, but our
motivation for doing this within PDDL+ is to allow task and
activity planning to take place in the context of medication
scheduling.
We will now briefly discuss some of our future research
directions.
7.1 Polymedicine
Our evaluation here considered only a single drug; the next
step is to look at polypharmacy. As almost a quarter of the
UK population are on at least three prescriptions (Scholes,
Faulding, and Mindell 2014), this is a substantial area of
interest.
In the case of painkillers, these are often complementary.
If a patient was only on one drug, it may be difficult to give
adequate pain relief due to the constraints of the drug it-
self. For example, paracetamol is an effective painkiller, but
the dosage restrictions mean it is a challenge to use it as a
monotherapy to give sufficient pain relief for a patient’s rou-
tine. Thus, if we take into account multiple painkillers (for
example paracetamol and ibuprofen), a combined schedule
of the two gives greater potential for pain management (tak-
ing both at the same time), and greater flexibility (taking
them at different times). The modifications to the model to
support this are relatively straightforward: rather than us-
ing a single pr variable, use multiple such variables (one for
each painkiller) and define conditions on pain relief to refer
to a weighted sum of these.
A more challenging case is where there are interactions
between medication. Ideally, two adversely interacting med-
ications would not be taken concomitantly, but it is some-
times unavoidable. To handle pharmacokinetic interactions
(one drug affects the rate of metabolism of another), the drug
decay processes would need to be updated. How to do this
well remains an open challenge.
7.2 Planning to avoid side effects
As discussed earlier, activity-specific drug plasma level re-
quirements can be incorporated into the preconditions of ac-
tions. This provides a mechanism for allocating doses of
medication around a patient’s daily routine.
A further consideration is the side-effects of medication,
as well as their desired effects. These side-effects place var-
ious constraints on how medication should be taken. For
instance, some medication require activities to take place be-
fore or after consumption. For example:
• Ibuprofen cannot be taken on an empty stomach, or it will
cause irritation, so an ideal plan would include meal-times
as well as medication times.
• Codeine causes drowsiness, so patients should avoid tak-
ing it before driving or operating machinery.
• Paracetamol conversely has no such constraints, but the
daily maximum dose is quite limited.
Considering a full plan of action for the day for a patient,
covering a wide range of their daily activities, there is good
scope to improve the management of their medication to re-
duce adverse effects.
7.3 Plan quality metrics
Thus far, our discussion has been on finding plans that meet
hard constraints, in terms of drug plasma levels during times
of the day, or during activities. We could hope to improve
a patient’s quality of life further by finding plans that are of
good quality.
The question then is what the quality metric should be. In
the context of pain relief, whilst a minimum pain relief may
be specified, the patient may for the sake of comfort wish to
avoid their pain relief getting quite down to this minimum.
A good candidate for a plan quality metric is to maximise
the minimum gap between pr and minpr seen during the
plan. With reference to Figure 5, this would have the effect
of delaying the second/third doses to avoid pr going quite so
low before the fourth dose was taken: the same medication
is taken, but the plan is subjectively better.
The caveat here though is that whilst ‘max of min’ or ‘min
of max’ metrics are common in various scheduling prob-
lems (e.g. Job-Shop Scheduling) they are non-standard in
planning, and cannot be elegantly expressed in PDDL+. As
OPTIC is already using a MIP to check that the precondi-
tions on solution plans hold, it already has the framework to
use more powerful plan metrics, by setting these as the MIP
objective function; we will be exploring this in our future
work.
8 Conclusions
In this paper, we presented a PDDL+ model of drug phar-
macokinetics, to provide a context in which to find solution
plans that consider, inter alia, the consumption of medica-
tion. As heuristic forward-search planners do well in terms
of causal reasoning, but often handle only linear dynamics,
we devised a linearise–validate approach for solving these
problems, by iteratively refining a linear approximation of
the domain using the diagnostic trace returned by the plan
validator, VAL.
An initial evaluation, implemented as a wrapper around
the planner OPTIC, demonstrates the feasibility of this ap-
proach. The results are exciting, opening up the opportunity
for future work both in terms of more comprehensive model
development, and more generally improving the range of
quality metrics that can be handled by PDDL-based planners
in hybrid domains.
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